Keel Point’s ARK Genomic Revolution ETF ARKG Stock Holding History
Bought
Maintained
Sold
Other funds holding ARKG
MCMC
Keel Point's ARKG Position: Q1 2022 in Review
Keel Point sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2022, closing a stake of 8,657 shares — an estimated $530K sold.
Keel Point first reported a position in ARKG in Q2 2020 and held it in 5 quarters. The position peaked at $907K in Q4 2020. 387 funds tracked by Wall St. Rank hold ARKG as of Q1 2022.
- Keel Point reported no remaining ARK Genomic Revolution ETF position as of Q1 2022 after selling out during the quarter.
- Keel Point sold 8,657 ARK Genomic Revolution ETF shares in Q1 2022, an estimated $530K.
- Keel Point first reported a position in ARK Genomic Revolution ETF in Q2 2020 and held it in 5 quarters.
- Keel Point's ARK Genomic Revolution ETF position peaked at $907K in Q4 2020.
- 387 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2022.
Based on Keel Point's 13F filing for Q1 2022, filed 27 Apr 2022.